Valuation : GlucoTrack

Market Cap 17.65L 15.21L 14.26L 13.02L 24.52L 17Cr 24.6L 1.69Cr 66.01L 8.52Cr 66.27L 64.83L 28Cr P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -21.72L -18.72L -17.55L -16.02L -30.18L -21Cr -30.27L -2.08Cr -81.23L -10Cr -81.54L -79.77L -35Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
78.19%
Yield 2024 *
-
Yield 2025 -
1 day-1.47%
1 week-18.83%
Current month-40.88%
1 month-6.00%
3 months-56.62%
6 months-81.81%
Current year-92.71%
1 week 0.28
Extreme 0.279
0.35
1 month 0.28
Extreme 0.279
0.9
Current year 0.25
Extreme 0.25
4.24
1 year 0.25
Extreme 0.25
14.14
3 years 0.25
Extreme 0.25
5,939.99
5 years 0.25
Extreme 0.25
38,999.92
10 years 0.25
Extreme 0.25
4,68,000.47
Manager TitleAgeSince
Chief Executive Officer 55 14/07/2026
Director of Finance/CFO 66 28/01/2025
Chief Operating Officer - 01/02/2025
Director TitleAgeSince
Director/Board Member 59 27/08/2024
Director/Board Member 56 25/08/2023
Chairman 64 13/02/2024
Date Insider Type Main position Quantity % Market Cap.
26/03/25 Free

Director

4,490 0.0431%
25/03/25 Free

Director

8,747 0.0840%
25/03/25 Free

Director

5,473 0.0526%
Change 5-day change 1-year change 3-year change Capi.($)
-1.47%-18.83%-93.44%-99.98% 17.65L
-0.78%-1.42%+2.49%+22.78% 5.05TCr
-6.00%-0.75%+442.41%+544.39% 4.46TCr
-0.24%+0.74%+38.69%+18.02% 4.31TCr
-1.55%-2.07%+23.08%+81.47% 4.17TCr
-0.31%-0.83%+16.15%+51.42% 3.32TCr
-1.79%-3.24%+27.00%+129.56% 1.68TCr
-0.58%-2.12% - - 1.63TCr
-0.88%-0.66%+11.60%+27.75% 1.46TCr
-1.66%-1.25%+78.59%+46.66% 1.39TCr
Average -1.53%-2.84%+60.73%+91.34% 2.75TCr
Weighted average by Cap. -1.70%-1.06%+95.71%+133.63%

Financials

2024 2025
Net sales - -
Net income -2.26Cr -1.95Cr -1.83Cr -1.67Cr -3.14Cr -215.97Cr -3.15Cr -22Cr -8.45Cr -109.02Cr -8.48Cr -8.3Cr -361.49Cr -1.94Cr -1.67Cr -1.57Cr -1.43Cr -2.69Cr -185.3Cr -2.7Cr -19Cr -7.25Cr -94Cr -7.28Cr -7.12Cr -310.16Cr
Net Debt -53.5L -46.1L -43.22L -39.46L -74.33L -51Cr -74.57L -5.13Cr -2Cr -26Cr -2.01Cr -1.96Cr -86Cr -39.37L -33.93L -31.81L -29.04L -54.7L -38Cr -54.87L -3.77Cr -1.47Cr -19Cr -1.48Cr -1.45Cr -63Cr
Logo GlucoTrack
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
28/26/28 $0.2820 -1.47% 26,52,291
27/26/27 $0.2862 -10.87% 16,92,958
26/26/26 $0.3211 -5.61% 5,74,581
25/26/25 $0.3402 +2.35% 5,62,154
24/26/24 $0.3324 -4.32% 2,24,483
  1. Stock Market
  2. Stocks
  3. GCTK Stock